AMICUS THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2012 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Amicus Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2012 to Q4 2024.
  • Amicus Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $19.2M, a 6.2% increase year-over-year.
  • Amicus Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $84.9M, a 1.36% decline year-over-year.
  • Amicus Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $84.9M, a 1.36% decline from 2023.
  • Amicus Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $86.1M, a 12.5% increase from 2022.
  • Amicus Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $76.5M, a 32.3% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.